Literature DB >> 21609150

Recovery from central nervous system changes following volatile substance misuse.

Kylie M Dingwall1, Sheree Cairney.   

Abstract

This review examines cognitive, neurological, and neuroanatomical recovery associated with abstinence from volatile substance misuse (VSM). Articles describing functional or structural brain changes longitudinally or cross-sectional reports comparing current and abstinent users were identified and reviewed. A significant lack of empirical studies investigating central nervous system recovery following VSM was noted. The few case reports and group studies identified indicated that cognitive and neurological impairments appear to follow a progression of decline and progression of recovery model, with the severity of impairment related to the duration and severity of misuse, blood lead levels among leaded petrol misusers, and the duration of abstinence for recovery. By contrast, severe neurological impairment known as lead encephalopathy from sniffing leaded petrol occurred as more catastrophic or abrupt damage to cerebellar processes that may never fully recover. Neuroanatomical damage may not recover even with prolonged abstinence.

Entities:  

Mesh:

Year:  2011        PMID: 21609150     DOI: 10.3109/10826084.2011.580221

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  3 in total

1.  Volatile substance misuse among high school students in South America.

Authors:  Marya Hynes-Dowell; Pedro Mateu-Gelabert; Helena Maria Taunhauser Barros; Jorge Delva
Journal:  Subst Use Misuse       Date:  2011       Impact factor: 2.164

Review 2.  Volatile solvents as drugs of abuse: focus on the cortico-mesolimbic circuitry.

Authors:  Jacob T Beckley; John J Woodward
Journal:  Neuropsychopharmacology       Date:  2013-08-19       Impact factor: 7.853

Review 3.  Volatile substance misuse: an updated review of toxicity and treatment.

Authors:  Jonathan B Ford; Mark E Sutter; Kelly P Owen; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.